Amandine Gouverneur

Amandine Gouverneur

Auto-generated profile, based on publicly available information

Amandine Gouverneur

IQVIA, RWS, France

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2022 in European Journal of Cancer
Verified
Journal Article
Closed access
PRPietro Rosellini
Pietro Rosellini
SASamuel Amintas
Samuel Amintas
CCCharline Caumont
Charline Caumont
RVRémi Veillon
Rémi Veillon
SGSigolène Galland-Girodet
Sigolène Galland-Girodet
PGPierre-Olivier Girodet
Pierre-Olivier Girodet

1 June 2017 in Journal of Clinical Epidemiology
Verified
Journal Article
Closed access
JFJean-Luc Faillie
Jean-Luc Faillie
PFPili Ferrer
Pili Ferrer
AGAmandine Gouverneur
Amandine Gouverneur
DDDamien Driot
Damien Driot
SBShoma Berkemeyer
Shoma Berkemeyer
LILuisa Ibáñez
Luisa Ibáñez

1 January 2018 in Journal of Geriatric Oncology
Verified
Journal Article
Closed access
AGAmandine Gouverneur
Amandine Gouverneur
FSFrancesco Salvo
Francesco Salvo
DBDriss Berdaï
Driss Berdaï
NMNicholas Moore
Nicholas Moore
AFAnnie Fourrier-Réglat
Annie Fourrier-Réglat
PNPernelle Noize
Pernelle Noize

26 October 2022 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
AGAmandine Gouverneur
Amandine Gouverneur
JAJérôme Avouac
Jérôme Avouac
CPClément Prati
Clément Prati
JCJean-Luc Cracowski
Jean-Luc Cracowski
TSThierry Schaeverbeke
Thierry Schaeverbeke
MTMarie-Élise Truchetet
Marie-Élise Truchetet

26 April 2024 in The Lancet Regional Health - Europe
Verified
Journal Article
Open access
PDPascal Demoly
Pascal Demoly
MMMathieu Molimard
Mathieu Molimard
JBJean-François Bergmann
Jean-François Bergmann
BDBertrand Delaisi
Bertrand Delaisi
AGAmandine Gouverneur
Amandine Gouverneur
PDPhilippe Devillier
Philippe Devillier
The only disease-modifying treatment currently available for allergic rhinitis (AR) is allergen immunotherapy (AIT). The main objective of the EfficAPSI real-world study (RWS) was to evaluate the impact of liquid sublingual immunotherapy (SLIT-liquid) on asthma onset and evolution in AR patients. An analysis with propensity score weighting was performed using the EfficAPSI cohort, comparing patients dispensed SLIT-liquid with patients dispensed AR symptomatic medication with no history of AIT (controls). Index date corresponded to the first dispensation of either treatment. The sensitive definition of asthma event considered the first asthma drug dispensation, hospitalisation or long-term disease (LTD) for asthma, the specific one omitted drug dispensation and the combined one considered omalizumab or three ICS ± LABA dispensation, hospitalisation or LTD. In patients with pre-existing asthma, the GINA treatment step-up evolution was analysed. In this cohort including 112,492 SLIT-liquid and 333,082 controls, SLIT-liquid exposure was associated with a significant lower risk of asthma onset vs. control, according to all definitions (combined: HR [95% CI] = 0.62 [0.60–0.63], sensitive: 0.77 [0.76–0.78], and specific: 0.67 [0.61–0.72]). Exposure to SLIT was associated with a one-third reduction in GINA step-up regardless baseline steps. In this national RWS with the largest number of person-years of follow-up to date in the field of AIT, SLIT-liquid was associated with a significant reduction in the risk of asthma onset or worsening. The use of three definitions (sensitive or specific) and GINA step-up reinforced the rigorous methodology, substantiating SLIT-liquid evidence as a causal treatment option for patients with respiratory allergies. Stallergenes Greer.

19 June 2014 in Drug Safety
Verified
Journal Article
Closed access
PDF file
HGHélène Géniaux
Hélène Géniaux
DADenise Assaf
Denise Assaf
GMGhada Miremont-Salamé
Ghada Miremont-Salamé
BRBénédicte Raspaud
Bénédicte Raspaud
AGAmandine Gouverneur
Amandine Gouverneur
FSFrancesco Salvo
Francesco Salvo